Cetuximab
Stage IVA Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma AJCC v7
National Cancer Institute (NCI)monoclonal_antibodyPhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 32/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Stage IVA Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma AJCC v7 cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
cc-5013 National Cancer Institute (NCI) | Phase 1 | CC |
Same molecule, other indications
Cetuximab is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →